Long-term follow-up for iECURE trial participants
Part of Brain & nervous system, Digestive system, Genetic & congenital, Hormones & metabolism clinical trials.
This study follows up with people who took part in an earlier iECURE trial (such as a gene therapy study) to check on their health over time. It collects information to see how safe and lasting the treatment effects are.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were previously enrolled in an iECURE study and you completed or stopped that study.
- Your parent or legal guardian agrees to follow the study rules.
- Your parent or legal guardian gave permission (and you agreed, if needed) before any data is collected.
- You are not joining another research drug or gene therapy trial that uses a different experimental treatment during this follow-up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy called ECUR-506 for baby boys under 9 months old with a severe form of OTC deficiency. The goal is to see if it can help their bodies process ammonia better, reducing the need for a strict protein-restricted diet and medications.
This study looks at liver tissue (under a microscope) in people with urea cycle disorders to better understand liver changes from the condition. It may help clinicians learn what to watch for and how to manage liver health, especially around liver biopsy or transplant.
This study follows up on people who previously received EG110A gene therapy in an earlier trial (EG110A-001-01) to monitor their health over a longer period. It helps doctors understand the lasting safety and effects of the treatment.
This is a follow-up (no new treatment) study for people who previously received a gene therapy made from their own cells for ADA-SCID. It mainly tracks long-term safety and whether a marker showing the gene change can still be found.
This study checks how people with cystinosis are doing long-term after finishing an earlier study medicine called CTNS-RD-04. It may help researchers understand the lasting effects and safety of that treatment over time.
This study is a follow-up check for people who were previously enrolled in certain NCI gene therapy treatment studies. It helps the research team monitor long-term effects and outcomes after treatment.
Hear when a new Ornithine Transcarbamylase Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.